BTIG analyst Timothy Chiang raised his price target on Sarepta to $170 and kept his Buy rating after the company's R&D day. The analyst notes that Sarepta is a "disruptor" in the Duchenne Muscular Dystrophy treatment market with its pipeline of gene therapy and RNA-splicing product candidates after its release of micro-dystrophin expression data well-exceeded his expectations. Chiang adds that he has updated his financial model to include the potential U.S. sales from this program, further noting that Sarepta can reach breakeven in the next 12 months while generating "significant operating leverage".